ALK upgrades guidance following convincing sales and savings
![Photo: ALK / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13188055.ece/ALTERNATES/schema-16_9/doc7h0tvwj5hs5h9a2icpx.jpg)
Allergy and immune therapy company ALK reports better sales than predicted for the second quarter of the year. The company has also saved some money on certain expenses and on postponing certain clinical activities, so now the Danish company is upgrading its revenue and earnings guidance for full-year 2021, according to a Monday press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
ALK nominates former Sanofi executive for board membership
For subscribers